Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

Share Price is delayed by 15 minutes
Get Live Data
36.60    0.10 (0.27%)
Bid:
36.50
Ask:
36.70
Spread: 0.20 (0.548%)
Market Cap: £26.87m
CAR Live PriceLast checked at - London Stock Exchange

Intraday Carclo Share Chart

Trading Statement

14 Apr 2023 07:00

RNS Number : 1808W
Carclo plc
14 April 2023
Β 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

Β 

14 April 2023

Β 

Carclo plc

Β 

("Carclo" or the "Group")

Β 

Full Year Trading Update

Β 

Carclo, a preferred and trusted partner of global customers, providing high-precision critical components to the life sciences, aerospace, optics, and technology industries, today provides an update on trading for the financial year ended 31 March 2023 ("FY 2023").

During FY 2023, the Company encountered multiple significant challenges, including the dissolution of a major manufacturing contract, the adverse effects of rising input costs on margins, and increasing interest rates. In response to this altered landscape, the Board shifted the Group's strategy to focus on operational excellence and cash generation. Although the final quarter of FY 2023 has shown early signs of the new strategy's benefits, the overall full-year profit performance is anticipated to be below the previous year. As a result of the new focus on cash generation, the Group expects to deliver an improvement in net debt compared to the position at the half year, whilst having continued to make significant pension deficit repair contributions. The suppressed Manufacturing Solutions margins and reduced Design & Engineering activity within our Carclo Technical Plastics (CTP) business have only been partially counterbalanced by increased manufacturing volumes in CTP and a robust performance from our Aerospace division.

Redefined Strategy

During the latter half of FY2023 it became clear that the cash-intensive top-line growth strategy was unsustainable in the current economic climate. As a result, the Board has refocused the Group's strategy on margin expansion through operational excellence and balance sheet strengthening via cash generation. Our investment priorities now lie in supporting existing projects and continuous improvement with a swift return on investment. While we have already begun implementing this new strategy and there is still much to accomplish, we are witnessing early positive indications of enhanced margins and cash generation as FY2023 concludes.

Β 

Banking Arrangements

The Board continues to work with its lending bank, HSBC, to ensure that there is appropriate ongoing financial support for the business as it implements the new strategy. HSBC remain supportive and the Group successfully reached an agreement with them to reset the interest cover covenant for 31 March 2023. Discussions are continuing with HSBC regarding the setting of appropriate covenants for the forthcoming financial year.

Β 

Carclo Technical Plastics (CTP)

The CTP division achieved a robust revenue performance, despite facing significant headwinds during the year. Activity in the Design & Engineering segment reduced from the very high level of the prior year, but remained above historical norms. The Manufacturing Solutions segment delivered significant revenue growth, primarily from our existing customers in the life sciences sector, demonstrating our ability to grow organically in our chosen markets.

Β 

However, significant margin challenges offset this revenue growth, particularly the unprecedented increase in input costs, including soaring energy prices. While we have been able to pass on some of the higher costs to customers, the time delay in doing so has caused a significant drop in operating margins during the year. The effect of the lower margins was only partially mitigated by increased manufacturing volumes and we therefore expect the divisional underlying operating profit to be materially lower than the prior year.

Β 

We previously announced the dissolution of a significant manufacturing contract and are engaged in ongoing discussions with the customer to reach a commercial agreement for this contract.

Β 

Our current focus is on margin recovery through operational efficiency and optimisation. We have begun our factory specialisation journey in the EMEA region, with our UK facility concentrating on long production runs and our Czech facility focusing on short and medium-run products, prioritising flexibility and rapid changeovers. We are now implementing this factory specialisation strategy in the US. Our Chinese and Indian operations demonstrate strong growth potential and enhance our global presence. We expect a steady recovery in operating margins in the near term as our new strategy starts to yield results.

Β 

Aerospace

Our Aerospace division is witnessing a robust recovery as the aviation industry rebounds, with sales approaching pre-COVID levels. The division's unique market position ensures margin resilience amid inflation, and we expect solid profits and operating cash flow for FY2023. Our focus lies in expanding sales within existing markets and creating high-precision, safety-critical solutions for specialised sectors.

Β 

Governance

The Board is dedicated to maintaining high governance standards and regulatory compliance. We have restructured the Board, separating the roles of Non-Executive Chairman and Chief Executive, in line with the Corporate Governance Code. Rachel Amey's recent appointment as a Non-Executive Director strengthens the Board, as her financial expertise will help ensure adherence to best practice in financial controls and governance.

Β 

Outlook

We remain dedicated to providing sustainable earnings growth and value creation for our stakeholders, despite the persistent challenges caused by inflationary pressures. Our new strategy emphasises cash generation, stability, operational excellence, and optimising our global footprint. We are implementing measures to enhance manufacturing and supply chain efficiency while minimising environmental impact. Our endeavours to optimise our global footprint will enable us to serve our customers better, support growth in key markets, and improve financial performance. We expect the business to deliver a substantially improved performance over the medium term as our focus shifts to enhancing margins and return on capital.

Β 

Β 

Β 

About Carclo plc

Carclo plc is a public company whose shares are quoted on the Main Market of the London Stock Exchange. The Group is a preferred and trusted partner of global customers, offering high-precision critical components that meet the needs of life sciences, aerospace, optics, and technology industries.

Β 

LEI: 21380078MEM399JPI956

Β 

Enquiries:

Carclo plc 01924 268040

Frank Doorenbosch - Chief Executive Officer

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTZZGMDVFNGFZM
Date   Source Headline
29th Apr 20264:59 pmRNSDirector Dealing – Late Notification
27th Apr 20267:00 amRNSHolding(s) in Company
23rd Apr 202610:34 amRNSHolding(s) in Company
23rd Apr 20267:00 amRNSTrading Update
24th Dec 202510:10 amRNSDirector/PDMR Shareholding
24th Dec 202510:10 amRNSDirector/PDMR Shareholding
25th Nov 20257:00 amRNSDirector/PDMR Shareholding
21st Nov 20257:00 amRNSHalf-year Financial Report
17th Nov 20257:00 amRNSNotice of Half Year Results
30th Sep 20256:20 pmRNSDirector/PDMR Shareholding
30th Sep 20256:14 pmRNSDirector/PDMR Shareholding
26th Sep 202512:30 pmRNSResult of AGM
26th Sep 20257:00 amRNSTrading Update
19th Sep 20255:58 pmRNSDirector/PDMR Shareholding
17th Sep 20257:00 amRNSChange of Auditor
11th Sep 20258:41 amRNSDirector/PDMR Shareholding
1st Sep 20257:30 amRNSRestoration - Carclo PLC
29th Aug 202511:55 amRNSNotice of AGM
29th Aug 20257:00 amRNSFull Year 2025 audited results
28th Aug 20257:00 amRNSNotice of Results and Investor Presentation
1st Aug 20257:30 amRNSSuspension - Carclo PLC
17th Jul 20254:42 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNSContract renewal strengthens revenue visibility
10th Jul 20257:00 amRNSTrading Statement & Delay in 2025 Audited Results
2nd May 202511:33 amRNSHolding(s) in Company
30th Apr 20257:00 amRNSTrading Statement
28th Apr 20255:06 pmRNSHolding(s) in Company
24th Apr 20254:02 pmRNSRefinancing Arrangements, Pension Scheme Valuation
3rd Apr 20257:00 amRNSHolding(s) in Company
6th Mar 202510:43 amRNSHolding(s) in Company
18th Feb 20255:10 pmRNSHolding(s) in Company
13th Feb 20257:00 amRNSCFO Appointment
19th Dec 20243:49 pmRNSHolding(s) in Company
5th Dec 20247:00 amRNSInterim Report and Accounts 30 September 2024
12th Nov 202411:11 amRNSNotice of Interim Results & Investor Presentation
10th Sep 20249:33 amRNSHolding(s) in Company
5th Sep 20241:30 pmRNSResult of AGM
5th Sep 20247:00 amRNSTrading Update
16th Aug 202412:32 pmRNSHolding(s) in Company
5th Aug 202412:11 pmRNSHolding(s) in Company
31st Jul 202410:00 amRNS2024 Annual Report & Accounts and Notice of AGM
30th Jul 20243:21 pmRNSHolding(s) in Company
24th Jul 20242:49 pmRNSHolding(s) in Company
24th Jul 202412:57 pmRNSHolding(s) in Company
23rd Jul 20243:48 pmRNSHolding(s) in Company
23rd Jul 20241:08 pmRNSDirector/PDMR Shareholding
18th Jul 20247:00 amRNSFinal Results
17th Jul 20241:07 pmRNSHolding(s) in Company
16th Jul 20247:00 amRNSNotice of Results
8th Jul 20248:51 amRNSBank Facilities Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.